The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Related to this article
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
The top 5 OncLive TV videos of the week.
Surufatinib plus serplulimab and cisplatin/etoposide produced a 69.8% ORR in advanced extrapulmonary neuroendocrine carcinoma.
Arcotatug tavatecan improved PFS and OS vs physician’s choice in previously treated, CLDN18.2-positive advanced gastric and GEJ cancer.
Overall survival benefit of daraxonrasib vs chemotherapy extends across RAS genotypes, chemotherapy regimens, and prior treatment settings.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Readers share their opinions on some of the most talked-about lung cancer abstracts they’re looking forward to seeing at ESMO 2026.
Advertisement
Advertisement
Trending on OncLive
1
Pembrolizumab Plus Chemo Misses EFS End Point in Cisplatin-Eligible MIBC
2
Surufatinib Plus Serplulimab and Chemo Shows Activity in First-Line Extrapulmonary NEC
3
Adding UV1 Vaccine to Olaparib/Durvalumab Maintenance Misses PFS End Point in BRCA-Wild Type Recurrent Ovarian Cancer
4